Saif A Bushnaq1, Fares Qeadan2, Tapan Thacker1, Mohammad Abbas3, Andrew P Carlson3. 1. Department of Neurology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA. 2. Clinical Translational Science Center, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA. 3. Department of Neurosurgery, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.
Abstract
BACKGROUND: Anticoagulation is the mainstay treatment for cerebral venous thrombosis (CVT). A subset of patients might deteriorate despite anticoagulation, and in such cases, endovascular therapy is recommended. METHODS: A retrospective review was performed on subjects with CVT from January 2005 to October 2016. The primary outcome was clinical deterioration. Bivariate analysis, multiple logistic regression modeling, and linear discriminant analysis were used to determine a predictive model for deterioration; the results from these models were used to construct a CVT score in order to measure the individual likelihood of deterioration. RESULTS: We identified 147 subjects with CVT. The majority were treated with anticoagulation (n = 109, 74.15%); 38 (25.85%) were found to have deterioration, 12 (8.16%) of whom underwent endovascular intervention. The most important risk factors of deterioration, per bivariate analysis, included decreased level of consciousness (odds ratio [OR] = 5.76; 95% confidence interval [CI] 2.59-12.77) and papilledema (OR = 4.52; 95% CI 1.55-13.18). The final multivariable model also included CVT location score (number of sinuses involved), oral contraceptive pill use, sodium level, platelet count, and seizure activity on presentation. This model had a predictive ability to identify deterioration of 83.2%, with a sensitivity of 71.4% and a specificity of 76.2%. Patients with a CVT score of ≥5 have at least 50% chance of deterioration. CONCLUSIONS: Decreased mental status, seizure activity, papilledema, number of involved sinuses, as well as sodium level and platelet count are the most important factors in predicting deterioration after CVT. This group may represent a subset of patients in whom early endovascular therapy may be considered.
BACKGROUND: Anticoagulation is the mainstay treatment for cerebral venous thrombosis (CVT). A subset of patients might deteriorate despite anticoagulation, and in such cases, endovascular therapy is recommended. METHODS: A retrospective review was performed on subjects with CVT from January 2005 to October 2016. The primary outcome was clinical deterioration. Bivariate analysis, multiple logistic regression modeling, and linear discriminant analysis were used to determine a predictive model for deterioration; the results from these models were used to construct a CVT score in order to measure the individual likelihood of deterioration. RESULTS: We identified 147 subjects with CVT. The majority were treated with anticoagulation (n = 109, 74.15%); 38 (25.85%) were found to have deterioration, 12 (8.16%) of whom underwent endovascular intervention. The most important risk factors of deterioration, per bivariate analysis, included decreased level of consciousness (odds ratio [OR] = 5.76; 95% confidence interval [CI] 2.59-12.77) and papilledema (OR = 4.52; 95% CI 1.55-13.18). The final multivariable model also included CVT location score (number of sinuses involved), oral contraceptive pill use, sodium level, platelet count, and seizure activity on presentation. This model had a predictive ability to identify deterioration of 83.2%, with a sensitivity of 71.4% and a specificity of 76.2%. Patients with a CVT score of ≥5 have at least 50% chance of deterioration. CONCLUSIONS: Decreased mental status, seizure activity, papilledema, number of involved sinuses, as well as sodium level and platelet count are the most important factors in predicting deterioration after CVT. This group may represent a subset of patients in whom early endovascular therapy may be considered.
Authors: C Zavanone; M Panebianco; M Yger; A Borden; D Restivo; C Angelini; A Pavone; G Grimod; C Rosso; S Dupont Journal: Rev Neurol (Paris) Date: 2016-12-27 Impact factor: 2.607
Authors: K Einhäupl; J Stam; M-G Bousser; S F T M De Bruijn; J M Ferro; I Martinelli; F Masuhr Journal: Eur J Neurol Date: 2010-10 Impact factor: 6.089
Authors: José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria Journal: Stroke Date: 2004-02-19 Impact factor: 7.914
Authors: Saif Bushnaq; Samer Abdul Kareem; Nicholas Liaw; Bader Alenzi; Muhammad Khaleeq Ahmed; Merna Bushnaq; Osama O Zaidat Journal: Front Neurol Date: 2021-12-17 Impact factor: 4.003
Authors: Yusuf Mehkri; Jeff A Valisno; Lorena Figueredo Rivas; Jairo Hernandez; Varun Jain; Aisha Elfasi; Justin De Prey; Calvin Hu; Bedirhan Tarhan; Ibrahim S Tuna; Hans H Shuhaiber Journal: Cureus Date: 2022-01-08